GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » YoY Rev. per Sh. Growth

RGTLF (Argent Biopharma) YoY Rev. per Sh. Growth : -85.19% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Argent Biopharma YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Argent Biopharma's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 was -85.19%.

Argent Biopharma's Revenue per Share for the six months ended in Dec. 2024 was $0.00.

Argent Biopharma YoY Rev. per Sh. Growth Historical Data

The historical data trend for Argent Biopharma's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma YoY Rev. per Sh. Growth Chart

Argent Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 175.33 14.45 9.09 -40.35 -97.93

Argent Biopharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.64 -73.33 -96.11 -100.68 -85.19

Argent Biopharma YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Argent Biopharma's YoY Rev. per Sh. Growth for the fiscal year that ended in Jun. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Jun. 2024 )
=(Revenue per Share (A: Jun. 2024 )-Revenue per Share (A: Jun. 2023 ))/ | Revenue per Share (A: Jun. 2023 ) |
=(0.016-0.773)/ | 0.773 |
=-97.93 %

Argent Biopharma's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2024 )
=(Revenue per Share (Q: Dec. 2024 )-Revenue per Share (Q: Dec. 2023 )) / | Revenue per Share (Q: Dec. 2023 )) |
=(0.004-0.027)/ | 0.027 |
=-85.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
ASX:EOF ASX:CAN ASX:IVX ASX:PER ASX:AGH ASX:EXL ASX:BP8 ASX:ECS ASX:NXS ASX:LGP ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
H5O0:Germany RGT:Australia
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Website
https://www.argentbiopharma.com
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.